Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

857 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Humbert M, et al. Among authors: beasley r. Allergy. 2005 Mar;60(3):309-16. doi: 10.1111/j.1398-9995.2004.00772.x. Allergy. 2005. PMID: 15679715 Clinical Trial.
Programming in asthma: the dice are loaded but not cast.
Hancox RJ, Beasley R. Hancox RJ, et al. Among authors: beasley r. Clin Exp Allergy. 2010 Dec;40(12):1717-8. doi: 10.1111/j.1365-2222.2010.03632.x. Clin Exp Allergy. 2010. PMID: 21059118 No abstract available.
Distinct clinical phenotypes of airways disease defined by cluster analysis.
Weatherall M, Travers J, Shirtcliffe PM, Marsh SE, Williams MV, Nowitz MR, Aldington S, Beasley R. Weatherall M, et al. Among authors: beasley r. Eur Respir J. 2009 Oct;34(4):812-8. doi: 10.1183/09031936.00174408. Epub 2009 Apr 8. Eur Respir J. 2009. PMID: 19357143 Free article.
Use of cluster analysis to define COPD phenotypes.
Weatherall M, Shirtcliffe P, Travers J, Beasley R. Weatherall M, et al. Among authors: beasley r. Eur Respir J. 2010 Sep;36(3):472-4. doi: 10.1183/09031936.00035210. Eur Respir J. 2010. PMID: 20930198 Free article. No abstract available.
857 results